e-Drug3D

1875

COPANLISIB

DISCONTINUED

INN
COPANLISIB

cas 1032568-63-0

CLASS

ANTINEOPLASTIC
PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR WITH INHIBITORY ACTIVITY PREDOMINANTLY AGAINST PI3K-ALPHA AND PI3K-DELTA ISOFORMS EXPRESSED IN MALIGNANT B CELLS
TREATMENT OF FOLLICULAR LYMPHOMA

ROUTE (list)

INTRAVENOUS

ATC code

L01EM02

PK parameters

VD 871 LITER
Cl 17.9 LITER / HOUR
PPB 84.2 PERCENT
t1/2 39.1 HOUR

Target

TARGET PHOSPHATIDYLINOSITOL-3-KINASE (PI3K)

PDB
5G2N (X-RAY STRUCTURE OF PI3KINASE GAMMA IN COMPLEX WITH COPANLISIB)

Ligand code = 6E2 (link to the list of PDB complexes)

Download experimental 3D coordinates of 6E2 with added hydrogens

DrugCentral

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform UNIPROT O00329 PIK3CD

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform UNIPROT P42336 PIK3CA

Download SDF file

5-Pyrimidinecarboxamide, 2-amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-

Formula:
C23H28N8O4

Calculated chemical properties:

MW 480.53
NB_atoms 35
XLogP 0.66
PSA 131.188
NB_HD 3
NB_HA 12
fsp3 0.43
Lipinski(0=no;1=yes) 0

FDA
NDA 209936 (label) INN (COPANLISIB DIHYDROCHLORIDE) ALIQOPA (BAYER HEALTHCARE) APPROVAL= AP YEAR= 2017 NEWMOLECULARENTITY DISCONTINUED